This weeks marks the publication of the EFPIA-EURORDIS Joint statement on Patient Access to Medicines for Rare Diseases.
The statement is based on an 18-month structured dialogue between the two organisations focused on identifying proposals that can improve access to orphan medicines across Europe. At the same time the statement recognises areas where the two organisations have different perspectives.
Europe needs a vibrant research ecosystem that will not only improve patient care, drive economic performance and resilience,...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.